Stempoint Capital »

Black Diamond Therapeutics shares owned by Stempoint Capital

Quarter-by-quarter ownership of Black Diamond Therapeutics (BDTX) shares owned by Stempoint Capital from 13F filings

Historical chart of Stempoint Capital investment in Black Diamond Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Black Diamond Therapeutics held by Stempoint Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Black Diamond Therapeutics by Stempoint Capital

Quarter filed Position value Share count Share price at filing
2024-06-30 $3.1M 674k 4.66

More positions owned by Stempoint Capital

Syndax Pharmaceuticals (SNDX)
Roivant Sciences SHS (ROIV)
Immunovant (IMVT)
Crinetics Pharmaceuticals In (CRNX)
Merus N V (MRUS)
Arcellx Common Stock (ACLX)
Amicus Therapeutics (FOLD)
Immunocore Hldgs Ads (IMCR)
Applied Therapeutics (APLT)
Merck & Co (MRK)
GSK Sponsored Adr (GSK)
Autolus Therapeutics Spon Ads (AUTL)
Cabaletta Bio (CABA)
Kalvista Pharmaceuticals (KALV)
Biohaven (BHVN)

View all positions for Stempoint Capital

Top funds holding Black Diamond Therapeutics

T. Rowe Price Investment Management
Bellevue Group
NEA Management Company
BlackRock
Vanguard Group
Vestal Point Capital
Tang Capital Management
Millennium Management
Artal Group
Geode Capital Management
T. Rowe Price Associates
Invesco
Kennedy Capital Management
State Street Corporation
Stempoint Capital

View all funds holding Black Diamond Therapeutics